Epidural Steroid Injections in Personal Injury: Medications, Pharmacy Liens, and the Demand Package

James Wong — Founder & Pharmacist, LienScripts | February 15, 2026 | 8 min read

Epidural steroid injections are among the most common interventional pain procedures in personal injury cases. Learn how ESIs work, which medications are involved, why insurers deny coverage, and how a pharmacy lien covers the oral medication component alongside the injection series.

What Is an Epidural Steroid Injection?

An epidural steroid injection (ESI) delivers corticosteroid medication — and often a local anesthetic — directly into the epidural space of the spine. The epidural space is the area between the dural sac surrounding the spinal cord and the inner surface of the spinal canal. By placing anti-inflammatory medication precisely at the site of nerve irritation, clinicians aim to reduce radicular pain, improve function, and allow patients to participate in physical therapy while their legal case progresses.

In personal injury, ESIs are most commonly ordered after motor vehicle accidents, workplace falls, or other trauma events that cause disc herniation, foraminal stenosis, or nerve root compression. These structural injuries produce the radiating, burning, or electric pain patterns patients describe as going down the arm (cervical) or leg (lumbar/sacral).

[!KEY] An ESI is not a cure — it is an anti-inflammatory and diagnostic tool. In personal injury, a successful ESI series corroborates the structural injury and supports causation in the demand package.

Types of Epidural Steroid Injections

There are three primary ESI approaches, and the approach chosen depends on the anatomy of the injury and the treating physician's assessment:

Interlaminar ESI — The needle is advanced between two adjacent vertebral laminae to deposit medication in the posterior epidural space. This is the most traditional approach and can be performed under fluoroscopic or CT guidance.

Transforaminal ESI — The needle targets the neural foramen (the opening through which a nerve root exits the spinal canal). This approach allows more targeted delivery to the ventral epidural space, where most disc herniations contact the nerve. It is often preferred for specific unilateral radiculopathy.

Caudal ESI — The needle enters through the sacral hiatus at the base of the spine. This approach is used primarily for lower lumbar or sacral nerve root involvement and is technically easier in patients with prior spinal surgery.

Cervical vs. Lumbar ESIs in Personal Injury

Cervical ESIs address nerve root compression at C4–5, C5–6, C6–7, or C7–T1. Rear-end collisions commonly produce cervical disc herniations that cause arm pain, hand numbness, and grip weakness. A cervical interlaminar or transforaminal ESI targets these levels. Cervical injections carry slightly higher procedural risk than lumbar because the epidural space is narrower.

Lumbar ESIs address L4–5 and L5–S1 most frequently. Low back injuries from motor vehicle accidents, slip-and-fall incidents, and workplace injuries often compress these nerve roots, producing classic sciatica: pain radiating down the buttock, thigh, and into the calf or foot. Lumbar transforaminal ESIs are the most targeted approach for unilateral disc herniations.

[!SOURCE] Manchikanti L, et al. "Comparative Effectiveness of Lumbar Interlaminar Epidural Injections in Managing Chronic Thoracic Pain: A Randomized, Double-Blind, Active Control Trial." Pain Physician. 2014;17(3):E233–E248. PMID: 24850107. Evidence for ESI efficacy in managing radicular pain from structural spine pathology.

Medications Used in ESIs

Corticosteroids are the primary active agents. The most commonly injected steroids in the United States include:

Methylprednisolone acetate (Depo-Medrol) — a particulate steroid; used in interlaminar and caudal approaches; not recommended for transforaminal use due to embolic risk with particulates.
Triamcinolone acetonide (Kenalog) — another particulate steroid; long history of use in caudal and interlaminar ESIs.
Dexamethasone — a non-particulate steroid; considered safer for transforaminal approaches because it does not carry embolic risk. Duration of effect may be shorter than particulates.
Betamethasone — non-particulate; sometimes used in transforaminal injections.

Local anesthetics are typically co-injected to confirm correct placement, provide immediate (if temporary) pain relief, and increase the volume of injectate. Lidocaine (1–2%) and bupivacaine (0.25–0.5%) are standard choices.

These injectables are administered by the interventional pain physician at the procedure facility — they are not dispensed by a retail or lien pharmacy. The pharmacy lien program's role focuses on the oral and topical medication component that surrounds the injection series.

How Pharmacy Liens Cover the Oral Medication Component

Before, between, and after ESI injections, patients require ongoing oral and topical medications to manage pain, reduce inflammation, and support nerve recovery. This is where a pharmacy lien program like LienScripts becomes essential.

Pre-injection medications: Patients typically need anti-inflammatory medications (NSAIDs such as meloxicam or naproxen), muscle relaxants (cyclobenzaprine, tizanidine, or methocarbamol), and sometimes oral corticosteroids (a methylprednisolone dose pack) to manage acute inflammation while waiting for the scheduled procedure.

Post-injection medications: After each injection, patients continue oral NSAIDs, may add gastroprotective agents (omeprazole or pantoprazole to protect the stomach during NSAID use), and often require adjuvant neuropathic pain agents (gabapentin or pregabalin) between injections when radicular pain partially returns.

Topical agents: Transdermal NSAIDs (diclofenac gel or the Flector patch), lidocaine patches, and compounded topical formulations are commonly used on the adjacent soft tissue between injections to reduce the systemic medication burden.

[!KEY] The pharmacy lien covers the oral and topical medications the patient cannot afford out of pocket — not the injectables administered at the procedure. Both components together tell a complete treatment story in the demand package.

Why Insurers Deny ESIs — and What It Means for the Case

Health insurers frequently deny ESIs on the grounds of "medical necessity" or require prior authorization with proof of failed conservative care (typically 6–12 weeks of physical therapy). Auto insurance MedPay and PIP benefits often do not cover injections at all, or exhaust quickly on earlier imaging and therapy.

For personal injury patients who lack active health insurance — or whose health insurer has issued a denial — interventional pain physicians often work on lien. The physician bills the settlement, not the patient's insurance. The pharmacy lien operates on the same principle for medications.

From a litigation standpoint, insurer denials are not necessarily bad news. An insurer's refusal to authorize an ESI — combined with documented ongoing radicular pain — demonstrates that the patient's suffering continued without adequate treatment. This supports higher general damages claims.

Documenting the ESI Series in the Demand Package

When building the demand package, the attorney should compile:

Referring physician notes confirming radiculopathy, imaging correlation (MRI showing disc herniation at the level injected), and the decision to proceed with ESI.
Interventional pain physician records for each injection: fluoroscopy or CT report, medication administered, patient response documented at follow-up.
Pharmacy lien records for all oral and topical medications filled on lien during the injection series — these demonstrate continuity of treatment and out-of-pocket value.
Physical therapy notes if PT continued alongside or between injections.
Outcome documentation: Did the injection series provide lasting relief? Did it fail, leading to surgical recommendation?

A three-injection series at an interventional pain clinic, combined with a full pharmacy lien medication record, can represent $15,000–$50,000 or more in billed treatment value — a significant component of the special damages calculation.

What Happens When ESIs Fail and Surgery Follows

Not all patients achieve adequate relief from an ESI series. Failure of conservative interventional treatment is a key inflection point in a personal injury case. When documented ESI failure precedes a surgical recommendation, it establishes medical necessity for the surgery itself.

For cervical cases, failed ESI often precedes anterior cervical discectomy and fusion (ACDF). For lumbar cases, failed ESI may lead to microdiscectomy, laminectomy, or spinal fusion. In both scenarios, the surgical case value increases substantially, and the pharmacy lien record becomes part of the pre-operative treatment history used by expert witnesses to establish the full arc of the patient's injury and care.

[!KEY] Document ESI failure explicitly. The pain physician's note stating "patient failed 3-injection ESI series with inadequate relief" is among the most valuable sentences in a high-value PI file.

Coordinating the Pharmacy Lien Alongside the ESI Pathway

LienScripts works with personal injury attorneys and pain management physicians to ensure the oral medication component is covered from the first prescription forward. When a patient is referred for an ESI series, the lien program can:

Dispense NSAIDs, muscle relaxants, and neuropathic pain agents immediately, before the first injection appointment.
Continue filling medications between injection appointments when partial pain returns.
Document every fill with lien paperwork that ties each prescription to the treating physician's care plan.
Provide the attorney with a complete medication summary for the demand package.

This coordination ensures patients are not forced to choose between filling their prescriptions and paying rent — and that every treatment dollar is documented as a lien balance recoverable at settlement.

Related Resources

Frequently Asked Questions

Does a pharmacy lien cover the injectable corticosteroids used in an ESI?

No. The injectables administered by the pain physician at the procedure facility (methylprednisolone, triamcinolone, dexamethasone) are billed by the facility or physician on their own lien or insurance claim. A pharmacy lien program covers the oral and topical medications — NSAIDs, muscle relaxants, gabapentinoids, and topical agents — that patients need before, between, and after injection appointments.

How many ESIs can a patient receive in personal injury?

Most pain management protocols limit ESIs to three injections per spinal region per year, both for safety reasons and because insurance and lien payers typically apply these guidelines. In PI, the standard approach is a diagnostic series of up to three injections, with response documented at each visit. If the series fails to provide lasting relief, the treating physician pivots to a surgical consultation or radiofrequency ablation.

Can an ESI denial by the health insurer help the personal injury case?

Yes, in some cases. When a health insurer denies an ESI as not medically necessary and the patient continues to suffer radicular pain, the denial record — combined with the pain physician's documented clinical findings — can support higher general damages. It demonstrates that the injury required intervention the patient could not access, prolonging suffering. Attorneys should preserve denial letters in the case file.

What is the difference between a transforaminal and interlaminar ESI in terms of demand package documentation?

Both approaches require fluoroscopy or CT guidance documentation. The distinction matters for damages because transforaminal ESIs are typically more targeted, more technically demanding, and often more expensive to perform. Including the specific approach in the demand package — along with the fluoroscopy report confirming needle placement at the affected nerve level — strengthens the medical necessity and causation narrative.